Patents by Inventor Akito Nishimuta

Akito Nishimuta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10481160
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: November 19, 2019
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Junya Tsuzaki, Hiroyuki Takahashi
  • Patent number: 10309957
    Abstract: To provide a marker for determining sensitivity to an anti-cancer agent, which can determine whether or not a patient has a therapeutic response to the anti-cancer agent, and cancer therapeutic means employing the marker.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: June 4, 2019
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Yuki Otani, Mitsuhisa Matsuo
  • Publication number: 20180038848
    Abstract: To provide a marker for determining sensitivity to an anti-cancer agent, which can determine whether or not a patient has a therapeutic response to the anti-cancer agent, and cancer therapeutic means employing the marker.
    Type: Application
    Filed: September 19, 2017
    Publication date: February 8, 2018
    Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke TANIGAWARA, Akito NISHIMUTA, Yuki OTANI, Mitsuhisa MATSUO
  • Patent number: 9797884
    Abstract: A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: October 24, 2017
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Yuki Otani, Mitsuhisa Matsuo
  • Publication number: 20170299597
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke TANIGAWARA, Akito NISHIMUTA, Junya TSUZAKI, Hiroyuki TAKAHASHI
  • Patent number: 9733256
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: August 15, 2017
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Junya Tsuzaki, Hiroyuki Takahashi
  • Patent number: 9459254
    Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: October 4, 2016
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Sayo Suzuki, Hidehiro Irie, Akito Nishimuta, Tetsuya Suzuki, Shinji Sugimoto
  • Publication number: 20150038522
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Junya Tsuzaki, Hiroyuki Takahashi
  • Patent number: 8945929
    Abstract: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: February 3, 2015
    Assignees: Keio University, Kabushiki Kaisha Yakult Honsha
    Inventors: Yusuke Tanigawara, Mitsuhiro Watanabe, Eri Arita, Akito Nishimuta, Yasuko Yamayoshi, Takeshi Matsuzaki, Shinji Sugimoto
  • Patent number: 8809362
    Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z of 152.99 to 153.00, a substance or a fragment thereof detected as a cation at m/z of 724.34 to 724.35, the peaks being determined by means of a mass spectrometer, glycerol 3-phosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, and glutathione, and a substance involved in a metabolic pathway of any of these substances.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 19, 2014
    Assignees: Keio University, Kabushiki Kaisha Yakult Honsha
    Inventors: Yusuke Tanigawara, Tetsuya Suzuki, Akito Nishimuta, Shinji Sugimoto, Yoshiaki Igarashi
  • Patent number: 8765713
    Abstract: A marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker, wherein the marker for determining sensitivity to an anti-cancer agent is a protein or a fragment, where in the protein or a fragment thereof exhibits a peak at m/z of 5,300 to 5,400, a peak at m/z of 6,130 to 6,230, a peak at m/z of 7,000 to 7,080 a peak at m/z of 7,840 to 7,920, a peak at m/z of 8,920 to 9,000, a peak at m/z of 12,440 to 12,560, a peak at m/z of 17,100 to 17,270, a peak at m/z of 18,290 to 18,470, a peak at m/z of 24,660 to 24,750, a peak at m/z of 35,980 to 36,290, a peak at m/z of 8,650 to 8,750, a peak at m/z of 9,100 to 9,200, a peak at m/z of 11,760 to 11,890, the peaks being determined by means of a mass spectrometer.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: July 1, 2014
    Assignees: Keio University, Kabushiki Kaisha Yakult Honsha
    Inventors: Yusuke Tanigawara, Sayo Suzuki, Yusuke Ikoma, Akito Nishimuta, Tetsuya Suzuki, Shinji Sugimoto
  • Publication number: 20140107068
    Abstract: A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.
    Type: Application
    Filed: February 24, 2012
    Publication date: April 17, 2014
    Applicants: KABUSHIKI KAISHA YAKULT HONSHA, KEIO UNIVERSITY
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Yuki Otani, Mitsuhisa Matsuo
  • Publication number: 20120220613
    Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 30, 2012
    Applicants: Kabushiki Kaisha Yakult Honsha, Keio University
    Inventors: Yusuke Tanigawara, Sayo Suzuki, Hidehiro Irie, Akito Nishimuta, Tetsuya Suzuki, Shinji Sugimoto
  • Publication number: 20120220618
    Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z of 152.99 to 153.00, a substance or a fragment thereof detected as a cation at m/z of 724.34 to 724.35, the peaks being determined by means of a mass spectrometer, glycerol 3-phosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, and glutathione, and a substance involved in a metabolic pathway of any of these substances.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 30, 2012
    Applicants: Kabushiki Kaisha Yakult Honsha, Keio University
    Inventors: Yusuke Tanigawara, Tetsuya Suzuki, Akito Nishimuta, Shinji Sugimoto, Yoshiaki Igarashi
  • Publication number: 20120214831
    Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 23, 2012
    Applicants: KABUSHIKI KAISHA YAKULT HONSHA, KEIO UNIVERSITY
    Inventors: Yusuke Tanigawara, Sayo Suzuki, Yusuke Ikoma, Akito Nishimuta, Tetsuya Suzuki, Shinji Sugimoto
  • Publication number: 20110003842
    Abstract: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
    Type: Application
    Filed: January 30, 2009
    Publication date: January 6, 2011
    Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Mitsuhiro Watanabe, Eri Arita, Akito Nishimuta, Yasuko Yamayoshi, Takeshi Matsuzaki, Shinji Sugimoto